Consequently, systemic inflammation is mitigated by downregulating the LPS/TLR4/NF-κB signaling pathway, a key driver of hepatic inflammation in NAFLD. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.